Neurostimulation Devices Market Size - By Product (Deep Brain, Gastric Electric, Spinal Cord, Sacral Nerve, Vagus Nerve Stimulator), By Application (Epilepsy, Pain Management, Essential Tremor, Urinary & Fecal Incontinence) & Forecast, 2023 - 2032

Some of the leading neurostimulation devices players are Abbott Laboratories, Aleva Neurotherapeutics S.A, BioControl Medical, Boston Scientific Corporation, Endostim, Innovative Health Solutions, Inc., Laborie, Inc., LivaNova PLC, Medtronic plc, RS Medical, and Synapse Biomedical, among many others.

U.S. neurostimulation devices market was worth USD 4 billion in 2022 and is estimated to expand at a robust CAGR from 2023 to 2032, owing to the increasing prevalence of neurological diseases coupled with the increasing R&D activities and adoption of minimally invasive techniques.

The market size of neurostimulation devices was worth USD 8.3 billion in 2022 and is projected to reach USD 25.5 billion by 2032, attributed to the surging demand for minimally invasive surgeries coupled with the rising prevalence of neurological disorders.

The spinal cord stimulator segment accounted for USD 3 billion in 2022, due to the rising prevalence of chronic pain and the increasing number of failed back surgeries.